EMMA News and Press, Emmaus Life Sciences Incorporation From 04/11/22

Emmaus Life Sciences (OTCPK:EMMA) notifies the launch of an innovative full-service telehealth solution accompanied by strategic partners, including Asembia LLC, US Bioservices Corporation and UpScript IP Holdings, LLC. The platform providers will handle on-line prescribing, dispensing a...

Emmaus Life Sciences Announces Launch of Full-Service Telehealth Solution PR Newswire Platform Providers Will Handle On-line Prescribing, Dispensing and Delivery of Endari® TORRANCE, Calif. , April 11, 2022 /PRNewswire/ -- Emmaus Life...

Emmaus Life Sciences Presented Positive Real-World Data on the Efficacy of Endari® in Preventing Acute Complications from Sickle Cell Disease at the 62nd Annual Scientific Meeting of the British Society for Haematology PR Newswire Sickle Cell Patients Treated With...

Emmaus Life Sciences press release (OTCPK:EMMA): FY GAAP EPS of -$0.32. Revenue of $20.62M (-11.1% Y/Y). For further details see: Emmaus Life Sciences GAAP EPS of -$0.32, revenue of $20.62M

Emmaus Life Sciences Reports 2021 Financial Results and Provides Business Update PR Newswire TORRANCE, Calif. , March 31, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA) , a commercial-stage biopharmaceutical company and leader in t...

Emmaus Life Sciences (OTCPK:EMMA) said Florida will become the latest state to approve adding its sickle cell disease (SCD) therapy Endari to the Florida Medicaid Preferred Drug List (PDL). The Florida Medicaid Pharmaceutical & Therapeutics Committee approved the addition of Endari,&...

Emmaus Life Sciences Announces Endari® To Be Added to the Florida Medicaid Preferred Drug List PR Newswire Florida Joins Other States in Eliminating the Need for Prior Authorization for Medicaid Patients TORRANCE, Calif. , March 29, 2022 /PRN...

Emmaus Life Sciences (OTCPK:EMMA) marketing authorization application for Endari to treat patients with sickle cell disease was approved in the United Arab Emirates (U.A.E.). The company said that during the review period, Endari was available in the U.A.E. on a named patient, or early a...

Emmaus Life Sciences Receives U.A.E. Marketing Authorization for Endari® PR Newswire TORRANCE, Calif. , March 23, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA) a commercial-stage biopharmaceutical company and leader in the treatme...

Emmaus Life Sciences' Real World Data on Endari® Accepted for E-Poster at the 62nd Annual Scientific Meeting of the British Society for Haematology PR Newswire TORRANCE, Calif. , March 4, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), ...